EA201492283A1 - Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) - Google Patents

Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)

Info

Publication number
EA201492283A1
EA201492283A1 EA201492283A EA201492283A EA201492283A1 EA 201492283 A1 EA201492283 A1 EA 201492283A1 EA 201492283 A EA201492283 A EA 201492283A EA 201492283 A EA201492283 A EA 201492283A EA 201492283 A1 EA201492283 A1 EA 201492283A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lysophosphatid
lpar
antagonists
acid receptors
substituted pyrazol
Prior art date
Application number
EA201492283A
Other languages
English (en)
Russian (ru)
Inventor
Стивен Димс Гэбриэль
Мэтью Майкл Гамильтон
Иминь Цянь
Ачютарао Сиддури
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201492283(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of EA201492283A1 publication Critical patent/EA201492283A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201492283A 2012-06-20 2013-06-17 Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) EA201492283A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
EA201492283A1 true EA201492283A1 (ru) 2015-04-30

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492283A EA201492283A1 (ru) 2012-06-20 2013-06-17 Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)

Country Status (22)

Country Link
US (1) US20150259295A1 (OSRAM)
EP (1) EP2864294A1 (OSRAM)
JP (1) JP2015520201A (OSRAM)
KR (1) KR20150011003A (OSRAM)
CN (1) CN104411690A (OSRAM)
AU (1) AU2013279510A1 (OSRAM)
BR (1) BR112014031108A2 (OSRAM)
CA (1) CA2869602A1 (OSRAM)
CL (1) CL2014003242A1 (OSRAM)
CO (1) CO7160077A2 (OSRAM)
CR (1) CR20140516A (OSRAM)
EA (1) EA201492283A1 (OSRAM)
HK (1) HK1206341A1 (OSRAM)
IL (1) IL236091A0 (OSRAM)
IN (1) IN2014DN09347A (OSRAM)
MA (1) MA37765A1 (OSRAM)
MX (1) MX2014014105A (OSRAM)
PE (1) PE20142445A1 (OSRAM)
PH (1) PH12014502364A1 (OSRAM)
SG (1) SG11201407229UA (OSRAM)
UA (1) UA109867C2 (OSRAM)
WO (1) WO2013189862A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2844982A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
MX382748B (es) 2013-03-15 2025-03-13 Epigen Biosciences Inc Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
US10023554B2 (en) 2014-06-27 2018-07-17 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
JP7301839B2 (ja) * 2017-12-19 2023-07-03 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのピラゾールn-連結のカルバモイルシクロヘキシル酸
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
KR20230019880A (ko) 2020-06-03 2023-02-09 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11980609B2 (en) 2021-05-11 2024-05-14 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698335A4 (en) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
PE20140879A1 (es) * 2010-12-07 2014-08-06 Amira Pharmaceuticals Inc Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
CA2844982A1 (en) * 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
WO2013189862A1 (en) 2013-12-27
HK1206341A1 (en) 2016-01-08
KR20150011003A (ko) 2015-01-29
SG11201407229UA (en) 2014-12-30
US20150259295A1 (en) 2015-09-17
CL2014003242A1 (es) 2015-03-20
UA109867C2 (ru) 2015-10-12
CO7160077A2 (es) 2015-01-15
IL236091A0 (en) 2015-02-01
PE20142445A1 (es) 2015-01-28
EP2864294A1 (en) 2015-04-29
CR20140516A (es) 2014-12-01
IN2014DN09347A (OSRAM) 2015-07-17
BR112014031108A2 (pt) 2017-06-27
MA37765A1 (fr) 2017-04-28
JP2015520201A (ja) 2015-07-16
MX2014014105A (es) 2015-03-05
CA2869602A1 (en) 2013-12-27
AU2013279510A1 (en) 2014-10-16
CN104411690A (zh) 2015-03-11
PH12014502364A1 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
EA201492285A1 (ru) Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
EA201492281A1 (ru) Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201691302A1 (ru) Новые гетероциклические соединения
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201591195A1 (ru) Новые хинолоновые производные
EA201600366A1 (ru) Производные бензимидазол-пролина
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201490152A1 (ru) Антагонисты trpm8 и их применение при лечении
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
EA201690888A1 (ru) Новые гетероциклические соединения
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
EA201700042A1 (ru) Соединения имидазопиридазина
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201692300A1 (ru) Производные карбоксамида
EA201690390A1 (ru) Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.